Anteris Technologies Global Corp. (AVR)
NasdaqGM · USD · Healthcare · Medical Devices
$5.86 (+1.38%) as of
Key statistics
- Market cap
- 571.11M
- Forward P/E
- -5.08
- EPS (TTM)
- -1.95
- Dividend yield
- 0.00%
- 52-week range
- 3.30 – 11.06
- Revenue (TTM)
- 2.24M
- Profit margin
- 0.00%
- Analyst target
- $14.00
- Volume
- 74.42k
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Toowong, QLD, Australia
- Employees
- 174
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.